CVC Credit is pleased to announce that it recently led the provision of senior facilities to support the acquisition of US Pharma Lab, a US-based contract development and manufacturing organisation (“CDMO”), by Biofarma Group (“Biofarma”) a leading European provider of food supplements, probiotic-based products and medical devices, owned by Ardian.
Biofarma is the European leader in the development, manufacturing, and packaging of food supplements, medical devices, probiotic-based products, and cosmetics. The group offers its clients an integrated offer, from research and development, to manufacturing and packaging of finished dosage form products. The company has six manufacturing facilities and three research and development centres across Italy and France, and employs more than 800 people.
US Pharma Lab specialises in the custom development, manufacture and distribution of innovative nutraceutical products including probiotics, vitamins, minerals, supplements, and premium dietary ingredients. Similar to Biofarma, it is driven by a focus on innovation, pharma-like manufacturing quality and a deep expertise in probiotics. The acquisition of US Pharma Lab’s will extend Biofarma’s presence in the attractive US market, provide a complementary technology offering and access to new customers.
Simone Zacchi, Managing Director at CVC Credit, commented: “This highly synergistic acquisition provides Biofarma with access to the large and attractive US market, as well as adding significant scale and efficiencies, meaning the newly combined group will have an advantage over peers. We are pleased to be supporting this transaction and sponsor Ardian in driving forward the growth strategies of the combined group.”
CVC Credit has considerable experience in the healthcare sector, through recent credit transactions … and our access to the knowledge of the wider CVC Network, which provides us with a significant advantage when pricing and diligencing new opportunities.
Andrew Davies Managing Partner and Co-Head of Private Credit at CVC Credit
Andrew Davies, Managing Partner and Co-Head of Private Credit at CVC Credit added: “We are very pleased to be supporting Ardian again, having built a strong relationship with the team following working with them on Neopharmed in 2022. CVC Credit has considerable experience in the healthcare sector, through recent credit transactions such as Doc Generici and Pharmathen, and our access to the knowledge of the wider CVC Network, provides us with a significant advantage when pricing and diligencing new opportunities.”